Stephen Jay Frank

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 648 citations · Full text

Medicine, Oncology, Pharmacology +11

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)

Richard D. Carvajal, Sophie Piperno‐Neumann, Ellen Kapiteijn et al. · Journal of Clinical Oncology · 2018 · 275 citations · Full text

Medicine, Oncology, Pharmacology +15

Radical cystectomy vs. chemoradiation in T2-4aN0M0 bladder cancer: A case-control study

Ofer N. Gofrit, Rony Nof, Dov Pode et al. · Urologic Oncology Seminars and Original Investigations · 2014 · 45 citations

Medicine, Surgery, Urology +12

Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma—A Retrospective Study

Reut Hadash‐Bengad, Emma Hajaj, Shiri Klein et al. · Frontiers in Oncology · 2020 · 45 citations · Full text

Medicine, Immunology, Oncology +17